By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    headphones can create health problems
    The Harmful Health Effects of Using Headphones
    September 24, 2021
    Headache causes
    4 Causes Of Headache You Probably Didn’t Know About
    December 28, 2021
    follow these steps to recover from your injury
    What Steps Should You Take to Recover More Quickly from an Injury?
    April 12, 2022
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Cash Transfers: Good for HIV/AIDS Too
    August 9, 2012
    unnecessary medical tests
    Eagerly Awaiting the Death of Defensive Medicine
    September 5, 2013
    Image
    Mobile Health Around the Globe – mHealth Fighting Malnutrition in India
    December 17, 2012
    Latest News
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Immunotherapy Trains the Immune System to Attack Cancer Cells
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > News > Immunotherapy Trains the Immune System to Attack Cancer Cells
NewsSpecialties

Immunotherapy Trains the Immune System to Attack Cancer Cells

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease.

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease. Cancer immunotherapy operates under a similar premise.

The Wall Street Journal recently published an article highlighting two drugs Bristol-Myers Squibb presented at the American Society of Clinical Oncology (ASCO) last weekend in Chicago.  The presentation came on the heels of last year’s regulatory approval for Yervoy, a drug that employs the immune system to treat advanced Melanoma. Researchers were impressed with its ability to provide long term survival in more than 20% of patients.  The stock peaked at just over $34.00 at today’s open, but has since declined.

Also mentioned in the WSJ were pharma giants, Roche, Merck, and GlaxoSmithKline as pursuers of immunotherapies. But neglected were smaller emerging companies with big ideas in the same field.

More Read

Is Eating Red Meat Bad For You?
Amping Up Community Dialogue
How Technology Shapes Dentistry’s Future
Chewing the Facts: The Impact of Dental Health on Your Well-being
Protecting Seniors From the West Nile Virus

Advaxis [ADXS], the 2012 winner of Best Therapeutic Vaccine in the VIE awards, is a development stage biotechnology company with the intent to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under exclusive license from the University of Pennsylvania that utilize live, attenuated Listeria monocytogenes bio-engineered to secrete antigen/adjuvant fusion proteins.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3, locally advanced cervical cancer, recurrent/refractory cervical cancer (India), and head & neckcancer. Over 15 distinct constructs are in various stages of development, developed directly by the company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. The stock has fluctuated over the last 3 months, peaking at $0.14 in March just after Best Therapeutic Vaccine win before settling at around $0.10 in recent weeks.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

In mid-May, Biovest announced it will file for market approval in the European Union for BiovaxID®. EMA approval would establish BiovaxID as the first cancer vaccine available in Europe for lymphoma patients.

The stock peaked mid February at $0.75 after being covered in several media outlets including Drug Discovery New, OneMedResarch and Fox News website which predicted the advance of Cancer vaccines in 2012 including BiovaxID® Lymphoma Vaccine. It has since been slowly declining and has hovered in the $0.45 range in recent weeks.

Stay tuned for an in-depth look into the advantages and disadvantages of big pharma’s new immunotherapy toys, and why a certain failure in Europe may be an omen. We’ll look at how the disruptive technologies in our wheelhouse stack up to the companies that big pharma has committed to.

 

TAGGED:cancerpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

9 Lifestyle Tweaks That Can Add Years to Your Life
9 Healthcare Lifestyle Tweaks That can Add Years to Your Life
lifestyle
July 11, 2025
car accident lawsuit
Let Your Lawyer Handle the Work Before You Pay Medical Costs
Policy & Law
July 6, 2025
women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025

You Might also Like

Caring for Aging Parents: Dealing with Memory Loss

April 2, 2013
immune boosting tips
Specialties

Immune Boosting Tips As Cold And Flu Season Approaches

September 14, 2020

2014: A Year of More Answers to Your Questions About Cancer

December 29, 2013

When Is External Peer Review The Right Choice For Hospitals?

October 20, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?